CN103751467A - 一种治疗腰背筋膜炎的中药组合物及其制备方法 - Google Patents
一种治疗腰背筋膜炎的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN103751467A CN103751467A CN201310750272.9A CN201310750272A CN103751467A CN 103751467 A CN103751467 A CN 103751467A CN 201310750272 A CN201310750272 A CN 201310750272A CN 103751467 A CN103751467 A CN 103751467A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- blood
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 123
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 40
- 206010052443 Myofascitis Diseases 0.000 title abstract description 5
- 210000003195 fascia Anatomy 0.000 claims abstract description 32
- 241000218176 Corydalis Species 0.000 claims abstract description 28
- 241000903946 Clematidis Species 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 45
- 229940079593 drug Drugs 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000010438 heat treatment Methods 0.000 claims description 26
- 206010061218 Inflammation Diseases 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 230000004054 inflammatory process Effects 0.000 claims description 20
- 210000000582 semen Anatomy 0.000 claims description 20
- 241000628997 Flos Species 0.000 claims description 19
- 230000008901 benefit Effects 0.000 claims description 19
- 238000000605 extraction Methods 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- 238000000108 ultra-filtration Methods 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 241000237636 Pheretima Species 0.000 claims description 13
- 241001489978 Eupolyphaga Species 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 9
- 238000002481 ethanol extraction Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000005469 granulation Methods 0.000 claims description 9
- 230000003179 granulation Effects 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 241001446509 Psoralea Species 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- -1 electuary Substances 0.000 claims description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000000274 adsorptive effect Effects 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 229940099259 vaseline Drugs 0.000 claims description 3
- 241001180876 Saposhnikovia Species 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 230000008719 thickening Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 120
- 210000004369 blood Anatomy 0.000 abstract description 109
- 230000000694 effects Effects 0.000 abstract description 56
- 210000003734 kidney Anatomy 0.000 abstract description 33
- 230000001737 promoting effect Effects 0.000 abstract description 28
- 230000017531 blood circulation Effects 0.000 abstract description 27
- 208000005392 Spasm Diseases 0.000 abstract description 14
- 208000007101 Muscle Cramp Diseases 0.000 abstract description 12
- 230000007246 mechanism Effects 0.000 abstract description 7
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 7
- 230000000474 nursing effect Effects 0.000 abstract description 5
- 241001050741 Dipsacus asperoides Species 0.000 abstract 2
- 241000112528 Ligusticum striatum Species 0.000 abstract 2
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241001289295 Asarum sieboldii Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 abstract 1
- 241001071795 Gentiana Species 0.000 abstract 1
- 241000243684 Lumbricus Species 0.000 abstract 1
- 241000195954 Lycopodium clavatum Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 241000951473 Schizonepeta Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 78
- 230000036407 pain Effects 0.000 description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 53
- 201000010099 disease Diseases 0.000 description 50
- 210000003205 muscle Anatomy 0.000 description 41
- 210000004185 liver Anatomy 0.000 description 27
- 206010016228 Fasciitis Diseases 0.000 description 26
- 208000006820 Arthralgia Diseases 0.000 description 20
- 210000000988 bone and bone Anatomy 0.000 description 19
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 208000037920 primary disease Diseases 0.000 description 17
- 210000001015 abdomen Anatomy 0.000 description 14
- 201000000736 Amenorrhea Diseases 0.000 description 13
- 206010001928 Amenorrhoea Diseases 0.000 description 13
- 206010019233 Headaches Diseases 0.000 description 13
- 231100000540 amenorrhea Toxicity 0.000 description 13
- 210000003414 extremity Anatomy 0.000 description 13
- 231100000869 headache Toxicity 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 11
- 231100000862 numbness Toxicity 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 241000700199 Cavia porcellus Species 0.000 description 10
- 208000019255 Menstrual disease Diseases 0.000 description 10
- 208000025747 Rheumatic disease Diseases 0.000 description 10
- 230000000552 rheumatic effect Effects 0.000 description 10
- 210000002435 tendon Anatomy 0.000 description 10
- 206010013935 Dysmenorrhoea Diseases 0.000 description 9
- 239000009636 Huang Qi Substances 0.000 description 9
- 206010027514 Metrorrhagia Diseases 0.000 description 9
- 238000001467 acupuncture Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000001771 impaired effect Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 238000010792 warming Methods 0.000 description 9
- 206010000087 Abdominal pain upper Diseases 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 8
- 208000005171 Dysmenorrhea Diseases 0.000 description 8
- 206010050031 Muscle strain Diseases 0.000 description 8
- 208000033809 Suppuration Diseases 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 208000008035 Back Pain Diseases 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 230000015271 coagulation Effects 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 208000035861 hematochezia Diseases 0.000 description 5
- 239000002398 materia medica Substances 0.000 description 5
- 230000002175 menstrual effect Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 206010040872 skin infection Diseases 0.000 description 5
- 206010042772 syncope Diseases 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 206010000077 Abdominal mass Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000008930 Low Back Pain Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010062575 Muscle contracture Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 208000010040 Sprains and Strains Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000006111 contracture Diseases 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000035617 depilation Effects 0.000 description 4
- 230000002951 depilatory effect Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 208000024756 faint Diseases 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 208000034656 Contusions Diseases 0.000 description 3
- 208000008967 Enuresis Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010019909 Hernia Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010024453 Ligament sprain Diseases 0.000 description 3
- 208000002740 Muscle Rigidity Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000004680 Rectal Fistula Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 206010047642 Vitiligo Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 206010002156 anal fistula Diseases 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003337 fertilizer Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 201000009890 sinusitis Diseases 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- NXJCRELRQHZBQA-UHFFFAOYSA-N 5,7-dimethoxy-1-benzopyran-2-one Chemical compound C1=CC(=O)OC2=CC(OC)=CC(OC)=C21 NXJCRELRQHZBQA-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010009346 Clonus Diseases 0.000 description 2
- 206010010947 Coordination abnormal Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010049949 Intercostal neuralgia Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000009519 contusion Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000001709 ictal effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000016290 incoordination Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 229940100691 oral capsule Drugs 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000009146 rhinoscleroma Diseases 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- FLNXBVJLPJNOSI-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 FLNXBVJLPJNOSI-UHFFFAOYSA-N 0.000 description 1
- JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- ATWHGWYKSFRYBN-UHFFFAOYSA-N Amygdaloside Natural products O1C(=O)C2(C)CCCC(C3CC4)(C)C2C1OCC3(C1)CC4C1(O)COC1OC(CO)C(O)C(O)C1O ATWHGWYKSFRYBN-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 description 1
- 241001427554 Corydiidae Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241001489980 Eupolyphaga sinensis Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 241000501743 Gentiana macrophylla Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001618 algogenic effect Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229960002544 cloperastine Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000005247 gettering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025005 lumbar spinal stenosis Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002097 psoas muscle Anatomy 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000000029 referred pain Diseases 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗腰背筋膜炎的中药组合物,内服药物为:当归10~20份,黄芪10~20份,丹参10~20份,桃仁10~20份,红花10~20份,香附10~20份,白芍10~20份,鸡血藤10~20份,川芎10~20份,秦艽10~20份,佛手10~20份,骨碎补10~20份,补骨脂10~20份,怀牛膝10~20份,川续断10~20份,延胡索10~20份,伸筋草10~20份;外用药物为:鸡血藤10~20份,川芎10~20份,赤芍10~20份,骨碎补10~20份,川续断10~20份,细辛10~20份,延胡索10~20份,荆芥10~20份,丹参10~20份,威灵仙10~20份,土鳖虫10~20份,地龙10~20份。本发明中药组合物配伍合理,一方面能修复受损筋膜、清除淤血、解除肌肉痉挛,一方面滋补肾阴、调养机理、行气活血,攻补结合,故在治疗筋膜炎上有标本兼治的功效。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物组份的医用配制品,特别涉及一种治疗腰背筋膜炎的中药组合物及其制备方法。
背景技术
腰背肌筋膜炎是指因寒冷、潮湿、慢性劳损而使腰背部肌筋膜及肌组织发生水肿、渗出及纤维性变,而出现的一系列临床症状。潮湿、寒冷的气候环境,是最多见的原因之一,湿冷可使腰背部肌肉血管收缩,缺血,水肿引起局部纤维浆液渗出,最终形成纤维织炎,慢性劳损为另一重要发病因素,腰背部肌肉,筋膜受损后发生纤维化改变,使软组织处于高张力状态。从而出现微小的撕裂性损伤,最后又使纤维样组织增多、收缩,挤压局部的毛细血管和末稍神经出现疼痛。其它如经常一个姿势坐着、缺少相应的活动、久坐电脑前及病毒感染、风湿症的肌肉变态反应等都是诱因。主要表现为腰背部弥漫性钝痛,尤以两侧腰肌及髂嵴上方更为明显。局部疼痛、发凉、皮肤麻木、肌肉痉挛和运动障碍。疼痛特点是:晨起痛,日间轻,傍晚复重,长时间不活动或活动过度均可诱发疼痛,病程长,且因劳累及气候变化而发作。查体时患部有明显的局限性压痛点,触摸此点可引起疼痛和放射。有时可触到肌筋膜内有结节状物,此结节称为筋膜脂肪疝。
慢性期病人的治疗以适当的休息,口服及外用消炎止痛药物以及肌松镇静药物,使用活血化淤的中药、适当的肌肉放松按摩为主。在腰肌劳损的腰背部酸痛症状缓解以后,应当积极加强腰背部肌肉的锻炼,调整工作生活节奏,加强腰部的保健,防止腰部受到风寒、外伤、劳损等不良因素的刺激,应当睡硬板床或者比较硬的席梦思床垫,避免睡行军床或者软的沙发,起床后要适当做一些腰部运动。否则,慢性腰肌劳损的症状可能非常容易反复发作。你如果反复发作腰肌劳损或腰肌筋膜炎,容易加速腰椎的退变,天长日久,可能容易引起较为严重的腰间盘突出症或者腰椎管狭窄症。
在临床上,腰肌劳损、下腰部劳损、慢性腰肌筋膜炎其实都是一个意思,大多数时候,不同的骨科医生可能根据自己不同的习惯,可以将同一个病人诊断为腰肌劳损或者腰肌筋膜炎、甚至下腰部劳损,但是他们选择的治疗方式都是一样,对于病情的估计也是一样的。所以如果这类病人在不同的医生那里得到了不同的诊断,完全没有必要因此而感到大惊小怪。
西医治疗筋膜炎,遵循其一贯以来分而治之的理念,“头痛医头,脚痛医脚”,忽视了人的整体性,中医认为筋膜炎,在外是因感受风寒湿邪、外伤劳损等,导致筋膜受损、瘀血凝滞、肌肉痉挛、经络阻闭、气血运行不畅;在内则是因肾气亏损、肝失所养,内外交迫,从而发病。中医内调外治之法,一方面能修复受损筋膜、清除淤血、解除肌肉痉挛,一方面滋补肾阴、调养机理、行气活血,攻补结合,故在治疗筋膜炎上有标本兼治的功效。中医有云:“人之疾病,由内以外,其流行于经络脏腑者,服药乃能驱之。若其病既有定所,在皮肤筋骨之间,可按而得者,用膏贴之,闭塞其气,使药性从毛孔而入其腠里通经贯络,或提而出之,或攻而散之,较服药尤为有力”。
建议中医治疗筋膜炎比较好,因为从中医学的角度讲筋膜炎是最贴切的。用中医内调外治之法,一方面能修复受损筋膜、清除淤血、解除肌肉痉挛,一方面滋补肾阴、调养机理、行气活血,攻补结合,故在治疗筋膜炎上有标本兼治的功效。日常护理有事也很重要,尤其是刚刚治疗好筋膜炎的患者特别需要注意护理。
背肌筋膜炎这一病名在传统医学中并不存在,其一般可归于“痹证”、“痹病”范畴。痹病泛指机体正气不足,卫外不固,邪气乘虚而入,致使气血凝滞,经络痹阻,引起相关系统疾病的总称。肢体经络为风寒湿之邪所闭塞,导致气血不通,经络痹阻,引起肌肉、关节、筋骨发生疼痛、楚、麻木、重着、屈伸不利等临床表现,故本病的病机关键主要在于寒湿瘀阻。
本病是临床的多发病、常见病之一,其常用治疗方法有针灸、拔罐、针刀、推拿、中药内服等,但常难以取得满意疗效。认为该病的形成有内、外两大因素。内因为气血虚弱,营卫表里不和,阴阳失调、筋骨失养;外因则是偶尔胸肋部闪挫,风寒湿邪入侵,瘀滞筋骨,阻塞脉络,致气血运行不通所致。气滞血瘀,风热入侵经络,毒热交炽,气血壅遏不通,不通则痛。肋间神经痛呈急性发病,可反复发作,时有发作性加剧。急诊病人因发病急,发作时疼痛剧烈,就诊时均希望能在短时间内缓解疼痛,但本病暂无理想的特效治疗。西药一般采取注射止疼剂,或激素治疗,缓解疼痛迅速,但持久性稳定性差,治标不治本。中药方剂随证加减,没有特定针对性,并且缓慢,见效慢,病患痛苦时间长,病患不易坚持。
发明内容
本发明所要解决的技术问题在于,针对本病急诊病人因发病急,发作时疼痛剧烈,就诊时均希望能在短时间内缓解疼痛,但本病暂无理想的特效治疗。西医治疗筋膜炎,遵循其一贯以来分而治之的理念,“头痛医头,脚痛医脚”,忽视了人的整体性。西药一般采取注射止疼剂,或激素治疗,缓解疼痛迅速,但持久性稳定性差,治标不治本。本病是临床的多发病、常见病之一,其常用治疗方法有针灸、拔罐、针刀、推拿、中药内服等,但常难以取得满意疗效。中药方剂随证加减,没有特定针对性,并且缓慢,见效慢,病患痛苦时间长,病患不易坚持;中药内服制剂和外用制剂的共同不足之处是,药效持续时间较短,针对性比较差,病患服从性差。
为解决这些技术难题,本发明提供了一种治疗腰背筋膜炎的中药组合物,由内服药物和外用药物组成,所述内服药物中各种原料的重量份数为:当归10~20份,黄芪10~20份,丹参10~20份,桃仁10~20份,红花10~20份,香附10~20份,白芍10~20份,鸡血藤10~20份,川芎10~20份,秦艽10~20份,佛手10~20份,骨碎补10~20份,补骨脂10~20份,怀牛膝10~20份,川续断10~20份,延胡索10~20份,伸筋草10~20份;
外用药物中各种原料的重量份数为:鸡血藤10~20份,川芎10~20份,赤芍10~20份,骨碎补10~20份,川续断10~20份,细辛10~20份,延胡索10~20份,荆芥10~20份,丹参10~20份,威灵仙10~20份,土鳖虫10~20份,地龙10~20份。
所述治疗腰背筋膜炎的中药组合物,其所述内服药物中各种原料的重量份数可以为:当归10~15份,黄芪10~15份,丹参10~15份,桃仁10~15份,红花10~15份,香附10~15份,白芍10~15份,鸡血藤10~15份,川芎10~15份,秦艽10~20份,佛手10~20份,骨碎补10~20份,补骨脂10~20份,怀牛膝10~20份,川续断10~20份,延胡索10~20份,伸筋草10~20份;
外用药物中各种原料的重量份数为:鸡血藤10~15份,川芎10~15份,赤芍10~15份,骨碎补10~15份,川续断10~15份,细辛10~15份,延胡索10~20份,荆芥10~20份,丹参10~20份,威灵仙10~20份,土鳖虫10~20份,地龙10~20份。
所述治疗腰背筋膜炎的中药组合物,其所述内服药物中各种原料的重量份数还可以为:当归10~20份,黄芪10~20份,丹参10~20份,桃仁10~20份,红花10~20份,香附10~20份,白芍10~20份,鸡血藤10~20份,川芎10~20份,秦艽10~15份,佛手10~15份,骨碎补10~15份,补骨脂10~15份,怀牛膝10~15份,川续断10~15份,延胡索10~15份,伸筋草10~15份;
外用药物中各种原料的重量份数还可以为:鸡血藤10~20份,川芎10~20份,赤芍10~20份,防风10~20份,川续断10~20份,细辛10~20份,延胡索10~15份,荆芥10~15份,丹参10~15份,威灵仙10~15份,土鳖虫10~15份,地龙10~15份。
为解决上述技术问题,本发明还提供一种治疗腰背筋膜炎的中药组合物的制备方法,其所述内服制剂的剂型为颗粒剂,其制备方法包括:
a、取原料药放入乙醇中浸泡,热提取2次,成膏状,为组分1;
b、药渣加水提取2次,浓缩过滤为膏状,为组分2;
c、将上述两种组分合并,浓缩成粉末掺入糊精制成颗粒剂。
所述步骤a中,可以取原料药加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,静置备用,成为组分1。
所述步骤b中,可以将上述乙醇提取过的原料药的药渣加10倍量水,加热回流提取2次,每次1~2小时,将2次提取液合并静置,成为组分2。
所述步骤c中,可以将组分1和组分2的合并,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06;上述滤液经体积为10L的大孔吸附树脂柱吸附后,用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除溶剂,得到药粉掺入糊精制成颗粒剂。
为解决上述技术问题,本发明再提供一种治疗腰背筋膜炎的中药组合物的制备方法,所述内服制剂的剂型为胶囊剂,制备方法包括:
将所述原料药去杂,晾干,粉碎成颗粒,加水浸泡1小时;将浸泡好的原料置多功能提取罐中加水煎煮二次;第一次加总药材10倍量的水,煎煮1.5~2小时,取煎液,滤过;第二次加总量7倍量的水,煎煮1~1.2小时,取两次煎液混合,滤过;将过滤的滤液置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量,直接干燥成粉末;装入胶囊中。
为解决上述技术问题,本发明也提供一种治疗腰背筋膜炎的中药组合物的制备方法,所述外用制剂的剂型为膏剂的制备方法包括以下步骤:
按照所述份数先将川续断、细辛和延胡索水蒸气法蒸馏,得到结晶物,作为组分1备用;取蒸馏后的药渣混合剩余原料加入5-10倍量的60-90%乙醇浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,80-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩,30分钟~45分钟,将浓缩液静置成浸膏状,药糊继续加热浓缩至浸膏状,静置备用,成为组分2;将蒸馏提取的组分1和乙醇提取的组分2混合,加凡士林成膏剂。
所述治疗腰背筋膜炎的中药组合物,其所述组合物的内服药物剂型可以为:糖衣片剂、薄膜衣片剂、肠溶衣片剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、丹剂、溶液剂或注射剂;所述组合物的外用药物剂型可以为:喷雾剂、粉剂、散剂、膏剂、纱布剂或贴膏剂。
本发明有益技术效果是:中医认为筋膜炎,在外是因感受风寒湿邪、外伤劳损等,导致筋膜受损、瘀血凝滞、肌肉痉挛、经络阻闭、气血运行不畅;在内则是因肾气亏损、肝失所养,内外交迫,从而发病。本发明内服外用结合,一方面能修复受损筋膜、清除淤血、解除肌肉痉挛,一方面滋补肾阴、调养机理、行气活血,攻补结合,故在治疗筋膜炎上有标本兼治的功效。本发明内服外用共同作用,能直达病灶,燥湿除脓、温补肾阳,益肾填精,滋补肾阴,益精养血,舒肝理气。其毒副作用小,使用方便,治愈时间短,治愈后不易复发。能创造较好的社会价值及经济利益。
具体实施方式
西医治疗筋膜炎,遵循其一贯以来分而治之的理念,“头痛医头,脚痛医脚”,忽视了人的整体性,中医认为筋膜炎,在外是因感受风寒湿邪、外伤劳损等,导致筋膜受损、瘀血凝滞、肌肉痉挛、经络阻闭、气血运行不畅;在内则是因肾气亏损、肝失所养,内外交迫,从而发病。中医内调外治之法,一方面能修复受损筋膜、清除淤血、解除肌肉痉挛,一方面滋补肾阴、调养机理、行气活血,攻补结合,故在治疗筋膜炎上有标本兼治的功效。中医有云:“人之疾病,由内以外,其流行于经络脏腑者,服药乃能驱之。若其病既有定所,在皮肤筋骨之间,可按而得者,用膏贴之,闭塞其气,使药性从毛孔而入其腠里通经贯络,或提而出之,或攻而散之,较服药尤为有力”。
建议中医治疗筋膜炎比较好,因为从中医学的角度讲筋膜炎是最贴切的。用中医内调外治之法,一方面能修复受损筋膜、清除淤血、解除肌肉痉挛,一方面滋补肾阴、调养机理、行气活血,攻补结合,故在治疗筋膜炎上有标本兼治的功效。日常护理有事也很重要,尤其是刚刚治疗好筋膜炎的患者特别需要注意护理。
背肌筋膜炎这一病名在传统医学中并不存在,其一般可归于“痹证”、“痹病”范畴。痹病泛指机体正气不足,卫外不固,邪气乘虚而入,致使气血凝滞,经络痹阻,引起相关系统疾病的总称。肢体经络为风寒湿之邪所闭塞,导致气血不通,经络痹阻,引起肌肉、关节、筋骨发生疼痛、楚、麻木、重着、屈伸不利等临床表现,故本病的病机关键主要在于寒湿瘀阻。
本病是临床的多发病、常见病之一,其常用治疗方法有针灸、拔罐、针刀、推拿、中药内服等,但常难以取得满意疗效。认为该病的形成有内、外两大因素。内因为气血虚弱,营卫表里不和,阴阳失调、筋骨失养;外因则是偶尔胸肋部闪挫,风寒湿邪入侵,瘀滞筋骨,阻塞脉络,致气血运行不通所致。气滞血瘀,风热入侵经络,毒热交炽,气血壅遏不通,不通则痛。肋间神经痛呈急性发病,可反复发作,时有发作性加剧。急诊病人因发病急,发作时疼痛剧烈,就诊时均希望能在短时间内缓解疼痛,但本病暂无理想的特效治疗。
黄芪以补虚为主,能补气固表,利尿托毒,排脓,敛疮生肌。用于气血不足、疮疡内陷、脓成不溃或久溃不敛者。黄芪具有很好的托毒生肌的功能,即久不愈合的脓肿化脓生肌。现代医学研究表明,黄芪内含而多种抗菌有效成分,而且能增强机体的免疫功能,因此还能用于预防某些传染病的发生。《本草逢原》载:“黄芪能补五脏诸虚,治脉弦自汗,泻阴火,去肺热,无汗则发,有汗则止。”是增进抵抗力和防御疾病的良药。
当归,其味甘而重,故专能补血,其气轻而辛,故又能行血,补中有动,行中有补,诚血中之气药,亦血中之圣药。大约佐之以补则补,故能养营养血,补气生精,安五脏,强形体,益神志,凡有形虚损之病,无所不宜。佐之以攻则通,故能祛痛通便,利筋骨,治拘挛、瘫痪、燥、涩等证。营虚而表不解者,佐以柴、葛、麻、桂等剂,大能散表卫热,而表不敛者,佐以大黄之类,又能固表。惟其气辛而动,故欲其静者当避之,性滑善行,大便不固者当避之。凡阴中火盛者,当归能动血,亦非所宜,阴中阳虚者,当归能养血,乃不可少。
川芎辛,温。入肝、胆经。行气开郁,法风燥湿,活血止痛。治风冷头痛旋晕,胁痛腹疼,寒痹筋挛,经闭,难产,产后瘀阻块痛,痈疽疮疡。用于月经不调,经闭痛经,瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。《本经》载其:主中风入脑头痛,寒痹,筋挛缓急,金创,妇人血闭无子。《别录》载其:″除脑中冷动,面上游风去来,目泪出,多涕唾,忽忽如醉,诸寒冷气,心腹坚痛,中恶,卒急肿痛,胁风痛,温中内寒。″是行气化瘀的良药
丹参苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。《纲目》载:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。丹参主要成分丹参酮有扩张血管、改善循环、解除血管内凝血等作用,具有活血化痕之功效,并能促进肝脏血液循环,利于肝细胞再生。
秦艽是中国重要的传统中药之一,始载于《神农本草经》,列为中品,用于风湿痹痛,筋脉拘挛,骨节酸痛,日晡潮热,小儿疳积发热。“秦艽主寒热邪气,寒湿风痹,肢节痛、下水、利小便。”《名医别录》称“秦艽能疗风,无问久新,通身挛急”。李时珍也指出“秦艽出秦中,以根作罗纹相交者为佳,故名秦艽,秦纠”。所以四种正品原植物中以大叶秦艽最为重要,作为秦艽药用历史悠久,并且处于黄土高原腹地的陕西、甘肃两省是其地道产区。秦艽是中药治疗风湿痹痛,关节病必不可少的药物。
红花性温,味辛。功能主治应用于活血通径、散瘀止痛。用于经闭、痛经、恶露不行、症瘕痞块、跌打损伤。《本草汇言》:红花,破血、行血、和血、调血之药也。主胎产百病因血为患,或血烦血晕,神昏不语;或恶露抢心,脐腹绞痛;或沥浆难生,;或胞衣不落,子死腹中,是皆临产诸证,非红花不能治。若产后血晕、口噤指搦;或邪入血室,谵语发狂;或血闷内胀,僵仆如死,是皆产后诸证,非红花不能定。凡如经闭不通而寒热交作,或过期腹痛而紫黑淋漓,或跌扑损伤而气血瘀积,或疮疡痛痒而肿溃不安,是皆气血不和之证,非红花不能调,红花活血通经、消肿止痛,有抑制血栓形成、抗炎、止痛作用,具有消除肾上腺素、去甲肾上腺素的收缩血管作用,有“通利经脉”作用。
桃仁苦、甘,平。归心、肝、大肠经。功能主治:活血祛瘀,润肠通便,止咳平喘。用于经闭,痛经,癓瘕痞块,跌扑损伤,肠燥便秘。桃仁提取液能明显增加脑血流量,增加犬股动脉的血流量,降低血管阻力,改善血流动力学状况。提取物能改善动物的肝脏表面微循环,并促进胆汁分泌。桃仁可使小鼠的出血及凝血时间明显延长,煎剂对体外血栓有抑制作用,水煎液有纤维促进作用。桃仁中含45%的脂肪油可润滑肠道,利于排便。桃仁能促进初产妇子宫收缩及出血。水煎剂及提取物有镇痛、抗炎、抗菌、抗过敏作用。桃仁中的苦杏仁苷有镇咳平喘及抗肝纤维化的作用。桃仁味苦甘而性平,能入心、肝、大肠,活血祛瘀作用甚广,可用治瘀血阻滞各种敝症。在治疗方面,善于治疗内痈,如肺痈;肠痈每持为要要药,是其具特有之性能欤。脂多质润,具润肠通便之功,唯晚近临床专以润肠通便则较少用。月经过多及孕妇忌用。桃仁与红花皆为活血祛瘀之药,作用均甚广泛,往往配合应用,唯桃仁善治肺痈肠痈,且有润肠通便之效;红花则善于活血调经。
佛手不仅有较高的观赏价值,而且具有珍贵的药用价值、经济价值。佛手全身都是宝,其根、茎、叶、花、果均可入药,辛、苦、甘、温、无毒,入肝、脾、胃三经,有理气化痰,止咳消胀、舒肝健脾和胃等多种药用功能。据史料记载,佛手的根可治男人下消、四肢酸软;花、果可泡茶,有消气作用;果可治胃病、呕吐、噎嗝、高血压、气管炎、哮喘等病症。据《归经》等载,佛手并具治鼓胀发肿病,妇女白带病及醒酒作用,是配制佛手中成药的主要原料。佛手不仅有较高的观赏价值,而且具有珍贵的药用价值。李时珍在《本草纲目》中记载:“佛手气味辛,温无毒;主治下气,除心头痰水;煮酒饮,治痰多咳漱;煮汤,治心下气痛。”佛手全身都是宝,根、茎、叶、花、果均可入药,性味辛、甘、苦、温、无毒,入肝、脾、胃、肺经,有疏肝解郁、燥湿化痰、理气和中的功效,常用于肝郁气滞、脾胃气滞和痰湿壅肺等证。药理研究表明,佛手主要含柠檬油素等香豆精类,尚含黄酮苷、橙皮苷、有机酸、挥发油等,对肠道平滑肌有明显的抑制作用,对乙酰胆碱引起的十二指肠痉挛有明显的解痉作用,可扩张冠状血管,增加冠脉的血流量,减缓心率和降低血压。
香附辛微苦甘,平功能主治:理气解郁,调经止痛。用于肝郁气滞,胸、胁、脘腹胀痛,消化不良,月经不调,经闭痛经,寒疝腹痛,乳房胀痛。《纲目》载其:散时气寒疫,利三焦,解六郁,消饮食积聚,痰饮痞满,跗肿,腹胀,脚气,止心腹、肢体、头、目、齿、耳诸痛,痈疽疮疡,吐血,下血,尿血,妇人崩漏带下,月候不调,胎前产后百病。
白芍入肝、脾经,养血柔肝,缓中止痛,敛阴收汗。治胸腹胁肋疼痛,泻痢腹痛,自汗盗汗,阴虚发热,月经不调,崩漏,带下,妇人血闭不通,消瘀血,能蚀脓,益女子血。《日华子本草》:治风、补劳,主女人一切病,并产前后诸疾,通月水,退热,除烦,益气,天行热疾,瘟瘴,惊狂,妇人血运,及肠风,泻血,痔瘘。发背,疮疥,头痛,明目,目赤努肉。赤色者多补气,白者治血。
鸡血藤性苦、甘,温。归肝、肾经,补血,活血,通络。用于月经不调,血虚萎黄,麻木瘫痪,风湿痹痛活血舒筋;养血调经,《本草纲目拾遗》载其能医手足麻木;肢体瘫痪;风湿痹痛;妇女有经不调;痛经。
骨碎补苦,温。归肾、肝经。补肾强骨,续伤止痛。用于肾虚腰痛,耳鸣耳聋,牙齿松动,跌扑闪挫,筋骨折伤;外治斑秃,白癜风。《本草正》:″疗骨中邪毒,风热疼痛,或外感风湿,以致两足痿弱疼痛。《本草述》:″治腰痛行痹,中风鹤膝风挛气证,泄泻,淋,遗精,脱肛。″
补骨脂温肾助阳,纳气,止泻。用于阳痿遗精,遗尿尿频,腰膝冷痛,肾虚作喘,五更泄泻;外用治白癜风,斑秃。芳香性中药。补肾助阳;纳气平喘;温脾止泻。主肾阳不足;下元虚冷;腰膝冷痛;阳痿遗精;尿频;遗尿;肾不纳气;虚喘不止;脾肾两虚;大便久泻;外用于白癜风;斑秃;银屑病。补骨脂又名破故纸、胡韭子,为豆科植物补骨脂的果实,其性温,味辛,入肾经,具有补肾助阳的功效,用于治疗肾虚冷泻、遗尿、滑精、小便频数、阳痿、腰膝冷痛、虚寒喘嗽等症,是一味壮火益土的常用要药。《本草经疏》:补骨脂,能暖水脏;阴中生阳,壮火益土之要药也。其主五劳七伤,盖缘劳伤之病,多起于脾肾两虚,以其能暖水脏、补火以生土,则肾中真阳之气得补而上升,则能腐熟水谷、蒸糟粕而化精微。
怀牛膝药效高,李时珍说它:滋补之功,如牛之力。牛膝气味苦酸平,主治寒湿痿痹、四肢拘挛,膝痛不可屈伸,逐血气,伤热火烂,久服轻身耐老。1.其中所含生物碱,具有良好的降压作用。2.所含的脱皮甾酮能改善肝功能,降低血浆胆固醇,有增强细胞活性的作用。3.富含牛膝多糖有明显的增强体液免疫功能作用。4.对人体因缺乏锌、锰所导致内分泌功能低下或腺体萎缩,生长缓慢、阳痿、不孕、习惯性流产等病理变化有较好的疗效。5.具有抗炎与镇痛作用。6.具有将胆囊、肾脏、膀胱、尿道的结石化解并排出体外的功能。7.其有效成分有一定的兴奋子宫、抗衰老作用。8.利尿、解痉作用。所以它的一味活血化瘀健体的良药。
川续断味苦,辛,性微温;归肝,肾经。补肝肾;强筋骨;调血脉;止崩漏。《别录》:主崩中漏血,金疮血内漏,止痛,生肌肉,踠伤,恶血,腰痛,关节缓急。《药性论》:主绝伤,去诸温毒,能宣通经脉。《日华子本草》:助气,调血脉,补五劳七伤,破症结瘀血,消肿毒,肠风,痔瘘,乳痈,瘰疬,扑损,妇人产前后一切病,面黄虚肿,缩小便,止泄精,尿血,胎漏,子宫冷。
延胡索主治心腹腰膝诸痛;月经不调;症瘕;崩中;产后血晕;恶露不尽;跌打损伤。有镇痛、镇静、催眠作用。活血;散瘀;理气;止痛。主心腹腰膝诸痛;月经不调;症瘕;崩中;产后血晕;恶露不尽;跌打损伤。用于胸胁、脘腹疼痛,经闭痛经,产后瘀阻,跌扑肿痛。镇痛作用:延胡索粉有镇痛作用,其止痛效价约为阿片的1/100;延胡索总碱、延胡索甲素、乙素、丑素、癸素均有镇痛作用,以乙素较强.各种剂型以醇制浸膏及粉剂作用强。《开宝本草》:主破血,产后诸病,因血所为者。妇人月经不调,腹中结块,崩中淋露,产后血运,暴血冲上,因损下血,或酒摩及煮服。
伸筋草性味归经苦辛温,入肝经。祛风散寒.除湿消肿,舒筋活络。用于风寒湿痹,筋脉拘挛疼痈。外用治跌打扭伤肿痛。《湖南药物志》:舒筋活血,补气通络。治腰痛,关节痛,闭经。《植物名实图考》:治筋骨,通关节。
外用制剂:
赤芍,行瘀、止痛、凉血、消肿。主治:治瘀滞经闭、疝瘕积聚、腹痛、胁痛、衄血、血痢、肠风下血、目赤、痈肿、跌扑损伤。赤芍能清血分实热,散瘀血留滞。该品功能与丹皮相近,故常与丹皮相须为用。但丹皮清热凉血的作用较佳,既能清血分实热,又能治阴虚发热;而赤芍只能用于血分实热,以活血散瘀见长。《本经》:主邪气腹痛,除血痹,破坚积,寒热疝瘕,止痛,利小便,益气。
威灵仙其根及茎入药具有风湿、通经络、消骨哽之功效。在现代临床实践中其新的用途不断的被发现,如治疗胆结石,跟骨骨刺、足跟痛、食管癌等。但用药中须注意的是,气血亏虚及孕妇慎服。祛风除湿,通络止痛,消痰水,散癖积。主治痛风顽痹、风湿痹痛,肢体麻木,膝冷痛,筋脉拘挛,屈伸不利,脚气,疟疾,症瘕积聚,破伤风,扁桃体炎,诸骨鲠咽。《开宝本草》:主诸风,宣通五藏,去腹内冷滞,心隔痰水久积,症瘕痃癣气块,膀胱宿脓恶水,腰膝冷疼及疗折伤。
荆芥味平,性温,无毒,清香气浓。荆芥为发汗,解热药,是中华常用草药之一。能镇痰、怯风、凉血。治流行感冒,头疼寒热发汗,呕吐。祛风;解表;透疹;止血。主感冒发热;头痛;目痒;咳嗽;咽喉肿痛;麻疹;痈肿;疮疥;衄血;吐血;便血;崩漏;产后血晕。用于感冒,头痛,麻疹,风疹,疮疡初起。《纲目》:散风热,清头目,利咽喉,消疮肿。治项强,目中黑花,及生疮,阴颓,吐血,衄血,下血,血痢,崩中,痔漏。
土鳖虫:土鳖虫是一味中药,为鳖蠊科昆虫地鳖(Eupolyphaga sinensisWalker)或冀地鳖(Steleophaga plancyi,即Boleny)的雌虫干燥体。具有破血逐瘀、续筋接骨之功效,并且有溶栓机制。其性寒、味成,有毒,能入心肝脾三经,具有逐瘀、破积、通络、理伤以及接骨续筋、消肿止痛、下乳通经等功效,是理血伤科要药,适用于癌瘕积聚、血滞经闭、产后瘀血腹痛、跌打损伤、木舌、重舌等病症。跌打损伤,筋伤骨折,瘀肿疼痛。本品成寒入血,主入肝经,性善走窜,能活血消肿止痛,续筋接骨疗伤,为伤科常用药,尤多用于骨折筋伤,瘀血肿痛。可单用研末调敷,或研末黄酒冲服;临床常与自然铜、骨碎补、乳香等同用。
地龙:《本草纲目》称之为具有通经活络、活血化瘀、预防治疗心脑血管疾病作用。地龙性寒味成。功能:清热、平肝、止喘、通洛。主治高热狂燥,惊风抽搐,风热头痛,目赤、半身不遂等。地龙提供取液有良好的定咳平喘的作用。
细辛,中药名,主治:祛风,散寒,行水,开窍。治风冷头痛,鼻渊,齿痛,痰饮咳逆,风湿痹痛。解表散寒;祛风止痛;温肺化饮;通窍。散寒祛风;止痛;温肺化饮;通窍。风寒表证;头痛,牙痛;风湿痹痛;痰饮咳喘;鼻塞;鼻渊;口疮。用于风寒感冒,头痛,牙痛,鼻塞鼻渊,风湿痹痛,痰饮喘咳。解热镇痛作用:细辛挥发油灌胃,对由温热刺激、伤寒菌苗和四氢β-萘胺所致的家兔发热模型有解热作用.并能使动物正常体温降至正常以下.细辛挥发油0。5ml/kg给家兔灌胃,对家兔由电刺激齿髓神经所致疼痛有镇痛作用,镇痛强度与安替比林0.5g/kg相当.细辛煎剂给小鼠灌胃亦有镇痛作用。
本发明内服蜜丸剂的制作过程为:将当归1000g,黄芪1000g,丹参1000g,桃仁1000g,红花1000g,香附1000g,白芍1000g,鸡血藤1000g,川芎1000g,秦艽1000g,佛手1000g,骨碎补1000g,补骨脂1000g,怀牛膝1000g,川续断1000g,延胡索1000g,伸筋草1000g,取原料加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成为组分1;将乙醇提取过的药渣放入10倍量水中,加热回流提取2次,每次提取时间为1~2小时,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成为组分2;将合并后组分1和组分2的膏状放入减压浓缩罐内,减压浓缩至相对密度为1.20,温度至60℃-70℃的浸膏;放入烘箱,烘干后冷却,与蜂蜜混在一起搓成细条,腊封包装。
本发明胶囊剂的制作过程为:将当归1200g,黄芪1200g,丹参1100g,桃仁1200g,红花1100g,香附1200g,白芍1200g,鸡血藤1100g,川芎1100g,秦艽1200g,佛手1100g,骨碎补1100g,补骨脂1200g,怀牛膝1200g,川续断1200g,延胡索1200g,伸筋草1200g,加入10倍量乙醇中加热提取2次,每次1~2小时,将2次提取液合并静置;将上述乙醇提取过的组份原料药材的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置。将上述两种提取液合并,减压回收乙醇并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,放入烘箱干燥得到组份药粉,装入胶囊制为胶囊剂。可以每12粒为一版。
本发明颗粒剂的制作过程为:取当归1200g,黄芪1300g,丹参1200g,桃仁1300g,红花1200g,香附1300g,白芍1200g,鸡血藤1200g,川芎1200g,秦艽1200g,佛手1200g,骨碎补1100g,补骨脂1200g,怀牛膝1200g,川续断1200g,延胡索1200g,伸筋草1300g,取原料加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成为组分1;上述乙醇提取过的组份原料药材的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置作为组分2;将组分1和组分2的合并,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06;上述滤液经体积为10L的大孔吸附树脂柱吸附后,用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除溶剂,得到药粉掺入糊精制成颗粒剂。
本发明外用膏剂的制备方法:
按照所述份数将川续断1000g、细辛1000g和延胡索1000g蒸馏成结晶,备用;取蒸馏后的药渣混合剩余原料鸡血藤1000g,川芎1000g,赤芍1000g,骨碎补1000g,荆芥1000g,丹参1000g,威灵仙1000g,土鳖虫1000g,地龙1000g,加入5-10倍量的60-90%乙醇浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,80-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩,30分钟~45分钟,将浓缩液静置成浸膏状,药糊继续加热浓缩至浸膏状,静置备用,成为组分2;将蒸馏提取的组分1和乙醇提取的组分2混合,成膏剂,加适量凡士林成膏剂。
也可以用上述方法得到的药膏浸泡纱布,制成纱布剂,每晚或空闲包住病患处,慢慢按摩半个小时-1个小时。
本发明外用贴膏剂的制备方法:
按照所述份数将川续断1200g、细辛1200g和延胡索1300g用水蒸汽蒸馏成结晶,备用;取蒸馏后的药渣混合剩余原料鸡血藤1200g,川芎1300g,赤芍1300g,骨碎补1300g,荆芥1300g,丹参1300g,威灵仙1300g,土鳖虫1300g,地龙1300g,加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成为组分1;上述乙醇提取过的组份原料药材的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述两种提取液合并,减压回收乙醇并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,成为组分2;将合并后组分1和组分2的膏状放入减压浓缩罐内,掺入粉碎的结晶粉末,减压浓缩至相对密度为1.20,温度至60℃-70℃的膏状;压入无纺纱布贴,制成贴膏剂。
药理学毒性试验
急性毒性实验资料
1、实验方法
将豚鼠背部脊柱两侧将脱毛剂均匀涂上,使去毛范围约40平方厘米。洗净脱毛剂归笼观察24小时,每组豚鼠分别涂本发明中药制剂外用喷雾剂0.2、0.4和0.8ml,分别含生药92mg、184mg和368mg),另一组涂溶媒0.8ml每日二次,连续一周,实验结束后,将豚鼠处死,心,肝,肾及脱毛皮肤做病理检验。
2、结果
上述三组用药豚鼠躯干脱毛区,未见局部皮肤有水肿、充血、红斑、出血点及溃疡。用药组豚鼠毛发色泽、摄食、四肢活动等对照组无明显差异,病理组织学检查,给药组心、肝、肾及脱毛皮与对照字比较也无明显差异。
结果提示,本发明中药外用制剂无局部刺激作用,也未见全身毒性表现。表明本发明中药外用制剂使用安全。
长期毒性实验资料
1、实验方法
将豚鼠随机份成4组,每组15只。在豚鼠背部脊柱两侧将脱毛剂均匀涂上,使其脱毛范围约40平方厘米。洗净脱毛剂,观察24小时后每组豚鼠分别涂本发明内服中药制剂胶囊剂0.2、0.4和0.8ml,分别含生药92、184和368mg),另一组涂溶媒0.8ml每日二次,连续30天,观察豚鼠的一般情况,实验结束后处死动物进行血液学、血液生化及病理学检查。
2、结果
上述三组用药豚鼠躯干去毛区,未见局部皮肤有水肿、充血、红斑、出血点及溃疡。用药组与对照组动物毛发色泽、摄食、四肢活动等对照组无明显差异,血液生化检查,用药组与对照组均在正常范围。病理组织学检查,实验各组心、肝、肾及局部皮肤均未见明显病变。提示,本发明中药制剂长期用药对局部皮肤及全身重要脏器均未见明显的毒性作用。试验结果表明:本发明中药制剂实验安全。
累计毒性实验:
本发明中药制剂内服胶囊剂对小鼠按7.69、19.18和43.21g生药/kg连续用药15周(1.0ml/100g体重,每天2次)及停药3周后,结果表明:本发明中药制剂对大鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药15周及停药3周后,大鼠各脏器均无明显改变。说明本发明中药制剂内服胶囊剂对大鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
药理学实验说明:
药理学实验:
微循环实验方法:
1.材料与方法:取50只小鼠,随机分成5组,每组10只(雌雄各半),对照组每鼠右耳涂生理盐水少许;阳性对照组每鼠右耳给予培元活血止痛膏,受试组分为本发明内服丸剂低剂量组400mg/kg/h、本发明内服丸剂中剂量组600mg/kg/h,本发明内服丸剂高剂量800mg/kg/h。15min后腹腔注射0.1%戊巴比妥钠0.1ml/10g麻醉动物,随后尾静脉注射0.1%肾上腺素0.1mL/10g,立即观察小鼠右耳微动静脉口径(μm)及0.2mm2毛细血管网点数.t检验处
理实验数据.
2结果与讨论
2.1.对微循环的影响
与对照组相比,受试组1对小鼠毛细血管开放数有明显增多(P<0.01);受试组2对微静脉口径和毛细血管开放数有显著增加(P<0.01);受试组3对小鼠微动、静脉口径及毛细血管开放数皆有增加(P<0.01);说明受试药能改善微循环,有活血化瘀作用(表1)。
表1、本发明对小鼠微动、静脉口径及毛细血管开放数的影响
临床试验:
背肌筋膜炎是指由于外伤、劳损或外感风寒等原因,引起人体肩背部富有白色纤维组织(如筋膜、肌膜、肌腱、韧带)的一种非特异炎性变化,临床以局部疼痛,肌肉痉挛和运动障碍症状为主。本病属于中医“筋伤”范畴,是临床的多发病、常见病之一,其常用治疗方法有针灸、拔罐、针刀、推拿、中药内服、中药熏蒸外洗等。笔者自2004年9月以来,采用内服外敷法治疗本病50例,并与常规治疗组作对照,取得了满意疗效,现总结如下。
1、临床资料
1.1一般资料
本资料共100例,均为本院外科门诊病例。其中男性66例,女性34例,男:女比为2∶1;年龄31~62岁,平均年龄42.23岁;病程5d~6年,病程小于1月者36例,1月~1年者34例,1年~6年者30例。
1.2诊断标准
按照国家中医药管理局1994年发布的《中医病证诊断疗效标准》进行诊断。凡背部酸痛,肌肉僵硬发板,有沉重感,疼痛常与天气变化有关,阴雨天及劳累后可使症状加重,可有外伤后治疗不当、劳损或外感病风寒等病史,背部有固定压痛点或压痛较为广泛,背部肌肉僵硬,沿骶棘肌行走方向常可触及条索状改变,肩背部功能活动可有障碍,X线摄片检查无阳性征。
1.3纳入标准
(1)符合前述背肌筋膜炎的诊断标准。
(2)年龄在18~65岁之间。
(3)患者自愿受试。
1.4排除标准
(1)合并急性软组织损伤,颈、腰椎病,肩周炎,风湿病。
(2)1周内接受过与本病相关的中西药治疗者。
(3)合并有心脑血管、肝、肾和造血系统等严重危及生命的原发性疾病以及精神病患者;妊娠或哺乳期妇女。
1.5疗效判定标准
参照《中医病证诊断疗效标准》和1997年国家卫生部制定发布的《中药新药临床研究指导原则》的中药新药治疗肌筋膜炎疗效判定标准。痊愈:背部疼痛消失,活动自如,无压痛,随访3个月无复发。显效:局部疼痛基本消失,无明显压痛,肢体活动大致正常,观察3个月病情无加重。有效:局部疼痛减轻,轻度压痛,肢体活动有改善,可参加轻工作,观察3个月病情无加重。无效:和治疗前相比,各方面均无改善。
2、治疗方法
2.1病例分组
按随机的原则将以上病例分为本发明组与对照组。本发明内服外敷组合治疗。局部穴位注射治疗对照组,其中局部穴位注射治疗组50例,其中男29例,女21例;年龄31~60岁,平均47.48岁,平均病程2.2年。本发明治疗组50例,其中男27例,女23例;年龄32~62岁,平均43.15岁;平均病程2.1年。两组资料统计分析无差异。
2.2治疗方法
本发明内服药物:当归12g,黄芪13g,丹参11g,桃仁13g,红花12g,香附13g,白芍11g,鸡血藤14g,川芎12g,秦艽14g,佛手13g,骨碎补13g,补骨脂12g,怀牛膝12g,川续断13g,延胡索14g,伸筋草13g。按实施例方法制成颗粒剂,每日三次,每次3-4粒。10天一个疗程。
外敷药物:鸡血藤14g,川芎13g,赤芍13g,骨碎补13g,川续断14g,细辛13g,延胡索13g,荆芥14g,丹参15g,威灵仙14g,土鳖虫14g,地龙14g按本发明实施例制成膏药,在痛处涂抹,然后按摩10分钟。
对比组:局部穴位注射治疗组:(1)取穴:有固定压痛点者取压痛点或其周围腧穴;压痛较广泛者,取压痛范围内的腧穴,如两肩胛间压痛取肺俞、大杼,背痛伴肩臂牵涉痛取天宗、肩井等;局部可触及硬结或条索状改变者取硬结或条索状改变的中心点。(2)注射用药:当归注射液(湖北麦克药业,十堰麦克制药有限公司生产,规格为2ml/支),维生素B12注射液(双鹤药业生产,规格为0.5mg/1ml)。(3)操作方法:用5ml一次性注射器抽取当归注射液4ml和维生素B12注射液1ml,充分混匀后备用。选取患部1~3个穴位,常规消毒后,将注射针斜刺入注射部位,得气(不强求)后,回抽无血液返流即可缓慢注入药液,每穴注射1~2ml,每日治疗1次,10次为1个疗程。
3治疗结果:见表1。
表1两组患者疗效比较 例(%)
两组显效率疗效比较,P<0.05,有显著性差异,表明本发明内服外敷治疗背肌筋膜炎的疗效优于常规治疗方法。
4讨论
背肌筋膜炎这一病名在传统医学中并不存在,其一般可归于“痹证”、“痹病”范畴。痹病泛指机体正气不足,卫外不固,邪气乘虚而入,致使气血凝滞,经络痹阻,引起相关系统疾病的总称。肢体经络为风寒湿之邪所闭塞,导致气血不通,经络痹阻,引起肌肉、关节、筋骨发生疼痛、楚、麻木、重着、屈伸不利等临床表现,故本病的病机关键主要在于寒湿瘀阻。
本病是临床的多发病、常见病之一,其常用治疗方法有针灸、拔罐、针刀、推拿、中药内服等,但常难以取得满意疗效。笔者在治疗本病时,认为本病的主要病机为气血凝滞,经络痹阻,采用内服外敷共同治疗,取得满意疗效。
现代药理研究证实,当归具有活血补血、温经通络功效,而丹参能营养神经,改善局部病灶病理状态。两药合用,有利于减少致痛物质的释放,共奏活血化瘀止痛之功。能激发经气,疏通经络,祛邪扶正。因此,本疗法发挥了药物双重作用,从而提高了临床疗效。
具体实施例:付某,男,32岁,工人,自述工作时提重物闪了腰,疼痛2个月,针灸、拔罐、针刀、推拿、中药内服都试过,疗效不好。曾到医院检查,排除腰肌劳损实质性病变。诊断为腰背筋膜炎。西医用止疼药控制住疼痛回去上班。不久复发,到本院治疗。主诉:后背,腰部仍感到隐隐作痛,有痛点。情绪紧张或劳累时增强。兼见口干舌燥,眼睛发涩,舌红苔少,脉细稍悬数。诊断为气血凝滞,经络痹阻,属于腰背筋膜炎。方用:内服当归13g,黄芪13g,丹参11g,桃仁13g,红花12g,香附13g,白芍11g,鸡血藤14g,川芎12g,秦艽14g,佛手13g,骨碎补13g,补骨脂12g,怀牛膝14g,川续断13g,延胡索14g,伸筋草13g。制成蜜炼丸剂,每日3次,每次2丸。
外用:鸡血藤14g,川芎13g,赤芍13g,骨碎补13g,川续断14g,细辛13g,延胡索13g,荆芥14g,丹参15g,威灵仙14g,土鳖虫14g,地龙14g按本发明实施例制成膏药,在痛处涂抹,然后按摩10分钟。用药5天后,感觉症状减轻,坚持一个月后痊愈。
Claims (10)
1.一种治疗腰背筋膜炎的中药组合物,其特征在于,由内服药物和外用药物组成,
所述内服药物中各种原料的重量份数包括:当归10~20份,黄芪10~20份,丹参10~20份,桃仁10~20份,红花10~20份,香附10~20份,白芍10~20份,鸡血藤10~20份,川芎10~20份,秦艽10~20份,佛手10~20份,骨碎补10~20份,补骨脂10~20份,怀牛膝10~20份,川续断10~20份,延胡索10~20份,伸筋草10~20份;
所述外用药物中各种原料的重量份数包括:鸡血藤10~20份,川芎10~20份,赤芍10~20份,骨碎补10~20份,川续断10~20份,细辛10~20份,延胡索10~20份,荆芥10~20份,丹参10~20份,威灵仙10~20份,土鳖虫10~20份,地龙10~20份。
2.根据权利要求1所述治疗腰背筋膜炎的中药组合物,其特征在于,
所述内服药物中各种原料的重量份数包括:当归10~15份,黄芪10~15份,丹参10~15份,桃仁10~15份,红花10~15份,香附10~15份,白芍10~15份,鸡血藤10~15份,川芎10~15份,秦艽10~20份,佛手10~20份,骨碎补10~20份,补骨脂10~20份,怀牛膝10~20份,川续断10~20份,延胡索10~20份,伸筋草10~20份;
所述外用药物中各种原料的重量份数包括:鸡血藤10~15份,川芎10~15份,赤芍10~15份,骨碎补10~15份,川续断10~15份,细辛10~15份,延胡索10~20份,荆芥10~20份,丹参10~20份,威灵仙10~20份,土鳖虫10~20份,地龙10~20份。
3.根据权利要求1所述治疗腰背筋膜炎的中药组合物,其特征在于,
所述内服药物中各种原料的重量份数包括:当归10~20份,黄芪10~20份,丹参10~20份,桃仁10~20份,红花10~20份,香附10~20份,白芍10~20份,鸡血藤10~20份,川芎10~20份,秦艽10~15份,佛手10~15份,骨碎补10~15份,补骨脂10~15份,怀牛膝10~15份,川续断10~15份,延胡索10~15份,伸筋草10~15份;
所述外用药物中各种原料的重量份数包括:鸡血藤10~20份,川芎10~20份,赤芍10~20份,防风10~20份,川续断10~20份,细辛10~20份,延胡索10~15份,荆芥10~15份,丹参10~15份,威灵仙10~15份,土鳖虫10~15份,地龙10~15份。
4.一种如权利要求1~3中任一项所述治疗腰背筋膜炎的中药组合物的制备方法,其特征在于,所述内服制剂的剂型为颗粒剂,其制备方法包括:
a、取原料药放入乙醇中浸泡,热提取2次,成膏状,为组分1;
b、药渣加水提取2次,浓缩过滤为膏状,为组分2;
c、将上述两种组分合并,浓缩成粉末掺入糊精制成颗粒剂。
5.根据权利要求4所述治疗腰背筋膜炎的颗粒剂的制备方法,其特征在于,所述步骤a中,取原料药加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,静置备用,成为组分1。
6.根据权利要求4所述治疗腰背筋膜炎的颗粒剂的制备方法,其特征在于,所述步骤b中,上述乙醇提取过的原料药的药渣加10倍量水,加热回流提取2次,每次1~2小时,将2次提取液合并静置,成为组分2。
7.根据权利要求4所述治疗腰背筋膜炎颗粒剂的制备方法,其特征在于,所述步骤c中,将组分1和组分2的合并,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06;上述滤液经体积为10L的大孔吸附树脂柱吸附后,用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除溶剂,得到药粉掺入糊精制成颗粒剂。
8.一种如权利要求1~3中任一项所述治疗腰背筋膜炎的中药组合物的制备方法,其特征在于,所述内服制剂的剂型为胶囊剂,制备方法包括:
将所述原料药去杂,晾干,粉碎成颗粒,加水浸泡1小时;将浸泡好的原料置多功能提取罐中加水煎煮二次;第一次加总药材10倍量的水,煎煮1.5~2小时,取煎液,滤过;第二次加总量7倍量的水,煎煮1~1.2小时,取两次煎液混合,滤过;将过滤的滤液置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量,直接干燥成粉末;装入胶囊中。
9.一种如权利要求1~3中任一项所述腰背筋膜炎的中药组合物的制备方法,其特征在于,所述外用制剂的剂型为膏剂的制备方法包括以下步骤:
按照所述份数先将穿续断、细辛和延胡索水蒸气法蒸馏,得到结晶物,作为组分1备用;取蒸馏后的药渣混合剩余原料加入5-10倍量的60-90%乙醇浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,80-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩,30分钟~45分钟,将浓缩液静置成浸膏状,药糊继续加热浓缩至浸膏状,静置备用,成为组分2;将蒸馏提取的组分1和乙醇提取的组分2混合,加凡士林成膏剂。
10.根据权利要求1~9中任一项所述治疗腰背筋膜炎的中药组合物,其特征在于,所述组合物的内服药物剂型为:糖衣片剂、薄膜衣片剂、肠溶衣片剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、丹剂、溶液剂或注射剂;所述组合物的外用药物剂型为:喷雾剂、粉剂、散剂、膏剂、纱布剂或贴膏剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310750272.9A CN103751467A (zh) | 2013-12-31 | 2013-12-31 | 一种治疗腰背筋膜炎的中药组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310750272.9A CN103751467A (zh) | 2013-12-31 | 2013-12-31 | 一种治疗腰背筋膜炎的中药组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103751467A true CN103751467A (zh) | 2014-04-30 |
Family
ID=50518894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310750272.9A Pending CN103751467A (zh) | 2013-12-31 | 2013-12-31 | 一种治疗腰背筋膜炎的中药组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103751467A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343394A (zh) * | 2015-11-16 | 2016-02-24 | 南阳理工学院 | 一种治疗高血压的中药组合物 |
| CN105497536A (zh) * | 2015-12-25 | 2016-04-20 | 青岛市第三人民医院 | 一种治疗背肌筋膜炎的中药药酒及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634312A (zh) * | 2004-09-23 | 2005-07-06 | 杨琰 | 治疗骨结核、骨髓炎、滑膜炎、脉管炎的药物 |
| CN102058823A (zh) * | 2009-09-21 | 2011-05-18 | 王解清 | 一种治疗人体颈椎、腰椎突出及增生的中药制剂 |
-
2013
- 2013-12-31 CN CN201310750272.9A patent/CN103751467A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634312A (zh) * | 2004-09-23 | 2005-07-06 | 杨琰 | 治疗骨结核、骨髓炎、滑膜炎、脉管炎的药物 |
| CN102058823A (zh) * | 2009-09-21 | 2011-05-18 | 王解清 | 一种治疗人体颈椎、腰椎突出及增生的中药制剂 |
Non-Patent Citations (3)
| Title |
|---|
| 刘元梅 等: "药罐结合治疗腰背筋膜炎57例", 《四川中医》, 31 December 1995 (1995-12-31), pages 46 * |
| 吴晓: "推拿配合中药熏蒸治疗腰背筋膜炎的护理体会", 《时珍国医国药》, vol. 14, no. 5, 31 December 2003 (2003-12-31), pages 286 - 287 * |
| 张立军 等: "中药配合理疗腰背筋膜炎42例临床观察", 《黑龙江中医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343394A (zh) * | 2015-11-16 | 2016-02-24 | 南阳理工学院 | 一种治疗高血压的中药组合物 |
| CN105497536A (zh) * | 2015-12-25 | 2016-04-20 | 青岛市第三人民医院 | 一种治疗背肌筋膜炎的中药药酒及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103656238B (zh) | 一种治疗风湿骨病的中药组合物 | |
| CN103860667B (zh) | 一种治疗腰肌劳损的中药组合物及其制备方法 | |
| CN101810685B (zh) | 一种治疗膝关节炎症的中药组合物及其制备方法 | |
| CN101455738B (zh) | 一种治疗湿疹的中药组合物及其制备方法 | |
| CN103751310B (zh) | 一种治疗筋膜炎的中药外用制剂及其制备方法 | |
| CN105435297A (zh) | 一种治疗女性痛经、宫寒、阴部湿疹的中草药卫生用品 | |
| CN102793883A (zh) | 一种治疗椎间盘突出、颈椎病、骨质增生的膏药 | |
| CN103751633A (zh) | 一种治疗下肢静脉曲张的中药组合物及其制备方法 | |
| CN104666579A (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
| CN104306495B (zh) | 一种治疗肩周炎的中药外用制剂及其制备方法 | |
| CN104666698A (zh) | 一种治疗膝关节滑膜炎的中药外用膏剂及其制备方法 | |
| CN109200144A (zh) | 一种中药组合物及其应用和膏药 | |
| CN102872286B (zh) | 一种治疗腰间盘突出的中药组合物及其制备方法 | |
| CN102626505B (zh) | 基于中草药的按摩膏及其制备方法 | |
| CN104826036A (zh) | 一种治疗乳腺增生的复合中药组合物及制备方法 | |
| CN104435169A (zh) | 一种治疗骨伤骨折的中药组合物及其制备方法 | |
| CN103736017A (zh) | 一种治疗肋间神经痛的中药组合物及其制备方法 | |
| CN102008674B (zh) | 一种治疗椎间盘突出、骨质增生和类风湿的膏药及其制备方法 | |
| CN103751710A (zh) | 一种治疗精索静脉曲张不育症的中药组合物及其制备方法 | |
| CN104056076A (zh) | 一种健骨药酒 | |
| CN103100017B (zh) | 一种缓解筋骨疼痛、关节疼痛的中药保健品及其制备方法 | |
| CN103751467A (zh) | 一种治疗腰背筋膜炎的中药组合物及其制备方法 | |
| CN104474114A (zh) | 一种治疗肾阳虚型腰肌劳损的中药组合物及其制备方法 | |
| CN100431577C (zh) | 一种治疗股骨头坏死、股骨颈骨折的药物及其制备方法 | |
| CN104398962A (zh) | 一种治疗脾肾两虚型腰肌劳损的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140430 |

